"Fenretinide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.
| Descriptor ID |
D017313
|
| MeSH Number(s) |
D02.455.326.271.665.202.495.270 D02.455.426.392.368.367.379.249.700.270 D02.455.849.131.495.270 D23.767.261.700.270
|
| Concept/Terms |
Fenretinide- Fenretinide
- N-(4-Hydroxyphenyl)-trans-Retinamide
- Fenretinimide
- N-(4-Hydroxyphenyl)retinamide
- 4-HPR
- 4-Hydroxyphenylretinamide
- 4 Hydroxyphenylretinamide
|
Below are MeSH descriptors whose meaning is more general than "Fenretinide".
Below are MeSH descriptors whose meaning is more specific than "Fenretinide".
This graph shows the total number of publications written about "Fenretinide" by people in this website by year, and whether "Fenretinide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fenretinide" by people in Profiles.
-
Fenretinide: a novel treatment for endometrial cancer. PLoS One. 2014; 9(10):e110410.
-
Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): an intergroup trial coordinated by the Eastern Cooperative Oncology Group. Med Oncol. 2011 Dec; 28 Suppl 1:S39-47.
-
Inhibitors of EGFR signaling retard cytotoxicity of fenretinide in rat gliosarcoma cells. Neurochem Res. 2008 Jan; 33(1):22-6.
-
Breast cancer and fenretinide, an analogue of vitamin A. Leukemia. 1994; 8 Suppl 3:S59-63.
-
Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer. J Clin Oncol. 1993 Mar; 11(3):474-7.